Bortezomib, thalidomide, and dexamethasone with or without daratumumab for transplantation-eligible patients with newly diagnosed multiple myeloma (CASSIOPEIA): health-related quality of life outcomes of a randomised, open-label, phase 3 trial

2020 ◽  
Vol 7 (12) ◽  
pp. e874-e883
Author(s):  
Murielle Roussel ◽  
Philippe Moreau ◽  
Benjamin Hebraud ◽  
Kamel Laribi ◽  
Arnaud Jaccard ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Newly Diagnosed ◽  
Health Related Quality ◽  
Life Outcomes ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Related Quality ◽  
Health Related

Health-related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study

2016 ◽  
Vol 17 (11) ◽  
pp. 1533-1542 ◽  
Author(s):  
Jaap C Reijneveld ◽  
Martin J B Taphoorn ◽  
Corneel Coens ◽  
Jacoline E C Bromberg ◽  
Warren P Mason ◽  
...  
Keyword(s):  
Quality Of Life ◽  
High Risk ◽  
Low Grade ◽  
Health Related Quality ◽  
Open Label ◽  
Phase 3 ◽  
Open Label Phase ◽  
Related Quality ◽  
Health Related
Sign in / Sign up

Export Citation Format

Share Document